The small molecule epidermal growth factor receptor (EGFR)-TKIs gefitinib and erlotinib have been approved for the treatment of non-small-cell lung cancer (NSCLC) and have exhibited dramatic antitumor activities. This evidence concerns the gene EGFR and non-small cell lung carcinoma.